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The Absorb everolimus-eluting bioresorbable 
vascular scaffold (Absorb BRS; Abbott Vascular, 
Santa Clara, CA, USA) promises vascular repair 
maintaining lumen diameter and restoring va-
somotion thereby reducing plaque volume. This 
technique allows an option  for bypass surgery 
thereafter (“leaving nothing behind”) [1]. Concerns 
arose from some trials and registries reporting 
higher rates of stent thrombosis and restenosis, 
although data are not unequivocal [2, 3]. So far, 
randomized controlled trials with BRS addressed 
simple and intermediate lesions. Whether BRS 
are also suited for more complex lesions is less 
known [4]. However, from a theoretical point of 
view, patients with more complex and especially 
long or multiple lesions may benefit most in the 
long-term from a therapy with BRS. The presented 
case was of a young patient with ST-elevation 
myocardial infarction (STEMI) undergoing multiple 
percutaneous coronary interventions (PCI) and 
BRS implantation.
A 55-year-old man was admitted to our hospital 
with an inferior STEMI, with peak high sensitivity-
-troponin (hsT) of 5333 ng/L and creatine kinase 
of 2131 U/L (normal value respectively < 14 ng/L 
and < 190 U/L). Coronary angiography revealed 
diffuse triple-vessel disease with subtotal oc-
clusion of the distal right coronary artery (RCA, 
Fig. 1A, white double circle), long significant le-
sions of the left circumflex artery (LCX) and mar-
ginal branch (Fig. 1B) as well as severe stenosis of 
the left anterior descending artery (LAD) and the 
first diagonal branch (D1) (Fig. 1C). Left ventricular 
ejection fraction was normal with inferior hypo-
kinesia. First, a 3.0 × 23 mm everolimus-eluting 
bioresorbable vascular scaffold (BRS, Absorb®, 
Abbott Vascular, Santa Clara, CA, USA) was implant-
ed in the distal RCA (“culprit lesion”) followed by 
a 3.5 × 18 mm BRS in the mid RCA. Proximally to 
the latter, a drug-eluting stent (Xience Alpine 4.0 × 
× 28 mm, Abbott) was implanted due to the large 
vessel size (Fig. 1D), with no overlapping of  the 
previous implanted BRS and no signs of dissection 
at the optical coherence tomography (OCT) control 
(Fig. 1E). The patient refused surgical revascular-
ization of the remaining lesions and the residual 
SYNTAX Score after PCI was 28. Therefore, the 
following day, the marginal branch and proximal 
LCX were stented again using two BRS (2.5 × 
× 28 mm and 3.0 × 28 mm) (Fig. 1F). Fluoroscopy 
showed a proximal-edge dissection, and the OCT 
confirmed a 4 mm long dissection (insert in Fig. 1F 
and Fig. 1G; Supplemental Video 1 — see 
journal website) that was treated with a 3.0 × 
8 mm BRS with optimal result (Supplemental 
Video 2 — see journal website). After 1 month, 
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control coronary angiography showed an optimal 
result after PCI. At that time four additional BRS 
were implanted in the mid-LAD (3.0 × 23 mm 
and 2.5 × 23 mm) and in the D1 (3.0 × 12 mm 
and 2.5 × 18 mm) (Fig. 1H) with no evidence of 
dissection at the following OCT control (Fig. 1; 
Supplemental Video 3 — see journal web-
site). Lesion preparation was always performed 
using compliant balloon with increasing diameter 
whereas needed, while post-dilatation was always 
carried out using non-compliant balloon with high 
inflation pressure. 181 mm-BRS-implantation 
achieved a full revascularization.
After 3 months the patient was again admi t-
ted to our hospital with an acute non-STEMI with 
a peak hsT of 569 ng/L and creatine kinase of 
193 U/L. Coronary angiogram revealed a mid-proxi-
mal LAD stenosis (Fig. 1J) adjacent to the proximal 
LAD BRS (scaffold restenosis, according to the 
current definition within 5 mm proximal and distal 
to the stent/scaffold [5]). The lesion was treated 
with a sirolimus drug-eluting stent. Re-analysis 
Figure 1. Multiple percutaneous coronary interventions and bioresorbable vascular scaffold (BRS) implantation in 
a young patient with acute coronary syndrome (ACS); A, B, C. Coronary angiography showed a diffuse triple-vessel 
disease with subtotal occlusion of the distal right coronary artery (RCA, A, white double circle), long significant le-
sions of the left circumflex artery (LCX) and marginal branch (B, white circles) as well as severe stenosis of the left 
anterior descending artery (LAD) and the first diagonal branch (D1) (C, white circles); D. Percutaneous coronary 
intervention (PCI) of the RCA: percutaneous transluminal coronary angioplasty (PTCA)/stenting of the distal RCA 
(“culprit lesion”) with a 3.0 × 23 mm everolimus-eluting bioresorbable vascular scaffold (BRS, Absorb®, Abbott Vas-
cular, Santa Clara, CA, USA) and of the mid RCA with a 3.5 × 18 mm BRS (the dotted white lines indicate the BRS); 
E. No signs of dissection at the optical coherence tomography (OCT) control; F and insert, G. PCI of the LCX on the 
following day with PTCA/stenting of the marginal branch and of the proximal LCX with two BRS (2.5 × 28 mm and 
3.0 × 28 mm, indicated by the dotted white lines). Control fluoroscopy showed a proximal-edge dissection, which 
was confirmed by OCT, that was treated with a 3.0 × 8 mm BRS; H, I. Control coronary angiography at 1 month. 
PCI of the mid-LAD (3.0 × 23 mm and 2.5 × 23 mm BRS, dotted white lines) and of the D1 (3.0 × 12 mm and 2.5 × 
× 18 mm BRS, dotted white lines). No evidence of dissection at the following OCT control; J. Mid-LAD stenosis after the 
D1 in the contest of a non-ST-elevation myocardial infarction-ACS after 3 months (the white arrow indicates the stenosis); 
K and insert. Re-analysis of the previously performed final angiography and OCT of the respecting BRS suggested 
as an underlying mechanism of this stenosis outside the scaffold, probably a micro-injury of the intima (“geographi-
cal missing”) due to the recommended post-dilatation (in our case a 3.0 × 15 mm non-compliant balloon at 24 bar); 
L. Longitudinal OCT with no signs of dissection.
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of the previously performed final angiography and 
OCT of the respecting BRS showed no signs of 
strut malapposition, edge dissection or thrombus 
formation. Therefore, the underlying mechanism 
of this stenosis outside the scaffold was most likely 
related to the recommended post-dilatation (in our 
case a 3.0 × 15 mm non-compliant balloon at 24 bar) 
when using BRS with consequent micro-injury of 
the intima (“geographical miss”) (Fig. 1K and insert, 
Fig. 1L) rather than a “classical scaffold stenosis”.
“Full Plastic-Jacket” using BRS is feasible 
and could be an option for patients with a diffuse 
disease, however, future studies are necessary to 
prove long-term benefit of this new therapeutic 
option [6]. BRS implantation in STEMI patients 
represents a potential option with a high proce-
dural success rate [7]. Nevertheless, due to lesion 
preparation and post-dilatation, which are manda-
tory to achieve an optimal result with BRS [8], 
there might be a potentially higher risk of early 
de novo stenosis or scaffold stenosis adjacent or 
outside the BRS.
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